Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Table 8 Mood and concentration profiles

Variable	T1	T2	T3	Time*group	Timegroupgender
POMS Tension
PLA	13 ± 4	13 ± 5	14 ± 4	Time p = 0.09	GTGe p = 0.61
LD	13 ± 3	14 ± 5	14 ± 4	G*T p = 0.98
HD	14 ± 4	15 ± 4	15 ± 4	G*T p = 0.98
POMS Depression
PLA	16 ± 3	16 ± 4	17 ± 4	Time p = 0.12	GTGe p = 0.47
LD	16 ± 2	17 ± 5	17 ± 3	G*T p = 0.55
HD	17 ± 2	18 ± 6	17 ± 5	G*T p = 0.55
POMS Anger
PLA	13.3 ± 2.4	13.9 ± 2.8	14.0 ± 3.7	Time p = 0.50	GTGe p = 0.97
LD	13.0 ± 1.8	13.7 ± 4.2	13.5 ± 3.6	G*T p = 0.65
HD	13.7 ± 2.4	13.4 ± 2.1	13.5 ± 2.9	G*T p = 0.65
POMS Vigor
PLA	22 ± 5	22 ± 6	21 ± 6	Time p = 0.021	*GTGe* p = 0.044
LD	23 ± 5	19 ± 6 ^†	23 ± 6 ^‡	*GT p = 0.006**
HD	21 ± 5	20 ± 6	19 ± 5	*GT p = 0.006**
POMS Fatigue
PLA	11 ± 3	12 ± 5	14 ± 5	Time p = 0.031	GTGe p = 0.79
LD	11 ± 4	12 ± 5	11 ± 4	G*T p = 0.41
HD	13 ± 5	14 ± 5	15 ± 6	G*T p = 0.41
POMS Confusion
PLA	12 ± 2	13 ± 3	13 ± 3	Time p = 0.64	GTGe p = 0.22
LD	13 ± 2	13 ± 2	13 ± 3	G*T p = 0.65
HD	13 ± 3	14 ± 4	13 ± 3	G*T p = 0.65
POMS Total
PLA	44 ± 13	45 ± 17	49 ± 16	Time p = 0.023	GTGe p = 0.62
LD	43 ± 10	50 ± 20	45 ± 15	G*T p = 0.50
HD	51 ± 15	58 ± 23	58 ± 20	G*T p = 0.50

Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
Symbols: ^‡, increase from corresponding T2 value within the male TC-LD group (p < 0.05); ^†, different from corresponding T1 value (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed

ISSN: 1550-2783